文献速递产科母胎医学

早孕期基于核磁共振的代谢组学分析可提高妊娠期糖尿病的预测能力

First-trimester nuclear magnetic resonance-based metabolomic profiling increases the prediction of gestational diabetes mellitus.
PubMed 文献 · Am J Obstet Gynecol · 2024-12-16

这项前瞻性研究纳入20,000名在11至13周孕龄接受常规孕期保健的孕妇,使用高通量核磁共振代谢组学平台评估代谢谱,并聚焦34种临床验证的生物标志物构建多变量逻辑回归模型预测妊娠期糖尿病。将生物标志物谱加入母体人口学特征和病史后,预测性能提高:曲线下面积从0.790升至0.840,10%假阳性率下检出率从50%升至56%,20%假阳性率下从63%升至73%。结论认为,将基于核磁共振的代谢组学分析加入危险因素可提供早孕期妊娠期糖尿病预测。

要点

  • 在20,000名11至13周孕妇中,基于核磁共振的代谢组学分析联合危险因素可提高妊娠期糖尿病预测。
  • 加入生物标志物谱后,曲线下面积从0.790升至0.840,10%假阳性率下检出率从50%升至56%。
  • 联合检测对胰岛素治疗的妊娠期糖尿病预测性能优于单纯饮食治疗者。

核心结论

  • 将基于核磁共振的代谢组学分析加入危险因素可提供早孕期妊娠期糖尿病预测。

研究设计与样本

  • 这是一项前瞻性研究,纳入20,000名在11至13周孕龄接受常规孕期保健的孕妇。
  • 使用高通量核磁共振代谢组学平台评估代谢谱,聚焦34种临床验证的生物标志物进行详细分析和风险建模。
  • 使用所有生物标志物生成多变量逻辑回归模型预测妊娠期糖尿病,数据按随机种子分为70%训练集和30%验证集。

主要发现

  • 包括胆固醇、甘油三酯、脂肪酸和氨基酸在内的多种代谢组学生物标志物浓度在发展为妊娠期糖尿病的女性和未发展者之间存在差异。
  • 加入生物标志物谱后,预测性能改善:曲线下面积从0.790升至0.840,10%假阳性率下检出率从50%(95%CI 44.3%-55.7%)升至56%(95%CI 50.3%-61.6%),20%假阳性率下从63%(95%CI 57.4%-68.3%)升至73%(95%CI 67.7%-77.8%)。
  • 联合检测对胰岛素治疗的妊娠期糖尿病预测性能(曲线下面积0.905;10%假阳性率下检出率76%,95%CI 67.5%-83.2%;20%假阳性率下检出率85%,95%CI 77.4%-90.9%)优于单纯饮食治疗的妊娠期糖尿病(曲线下面积0.762;10%假阳性率下检出率47%,95%CI 37.7%-56.5%;20%假阳性率下检出率64%,95%CI 54.5%-72.7%)。
  • 校准图显示观察到的妊娠期糖尿病发生率与联合风险模型预测的发生率之间具有良好一致性。
  • 在排除20周孕龄前诊断为妊娠期糖尿病的64名女性的敏感性分析中,曲线下面积与整个队列结果相比差异可忽略不计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current strategies for predicting gestational diabetes mellitus demonstrate suboptimal performance. OBJECTIVE: To investigate whether nuclear magnetic resonance-based metabolomic profiling of maternal blood can be used for first-trimester prediction of gestational diabetes mellitus. STUDY DESIGN: This was a prospective study of 20,000 women attending routine pregnancy care visits at 11 to 13 weeks' gestation. Metabolic profiles were assessed using a high-throughput nuclear magnetic resonance metabolomics platform. To inform translational applications, we focused on a panel of 34 clinically validated biomarkers for detailed analysis and risk modeling. All biomarkers were used to generate a multivariable logistic regression model to predict gestational diabetes mellitus. Data were split using a random seed into a 70% training set and a 30% validation set. Performance of the multivariable models was measured by receiver operating characteristic curve analysis and detection rates at fixed 10% and 20% false positive rates. Calibration for the combined risk model for all gestational diabetes mellitus was assessed visually through a figure showing the observed incidence against the predicted risk for gestational diabetes mellitus. A sensitivity analysis was conducted excluding the 64 women in our cohort who were diagnosed with gestational diabetes mellitus before 20 weeks' gestation. RESULTS: The concentrations of several metabolomic biomarkers, including cholesterol, triglycerides, fatty acids, and amino acids, differed between women who developed gestational diabetes mellitus and those who did not. Addition of biomarker profile improved the prediction of gestational diabetes mellitus provided by maternal demographic characteristics and elements of medical history alone (before addition: area under the receiver operating characteristic curve, 0.790; detection rate, 50% [95% confidence interval, 44.3%-55.7%] at 10% false positive rate; and detection rate, 63% [95% confidence interval, 57.4%-68.3%] at 20% false positive rate; after addition: 0.840; 56% [50.3%-61.6%]; and 73% [67.7%-77.8%]; respectively). The performance of combined testing was better for gestational diabetes mellitus treated by insulin (area under the receiver operating characteristic curve, 0.905; detection rate, 76% [95% confidence interval, 67.5%-83.2%] at 10% false positive rate; and detection rate, 85% [95% confidence interval, 77.4%-90.9%] at 20% false positive rate) than gestational diabetes mellitus treated by diet alone (area under the receiver operating characteristic curve, 0.762; detection rate, 47% [95% confidence interval, 37.7%-56.5%] at 10% false positive rate; and detection rate, 64% [95% confidence interval, 54.5%-72.7%] at 20% false positive rate). The calibration plot showed good agreement between the observed incidence of gestational diabetes mellitus and the incidence predicted by the combined risk model. In the sensitivity analysis excluding the women diagnosed with gestational diabetes mellitus before 20 weeks' gestation, there was a negligible difference in the area under the receiver operating characteristic curve compared with the results from the entire cohort combined. CONCLUSION: Addition of nuclear magnetic resonance-based metabolomic profiling to risk factors can provide first-trimester prediction of gestational diabetes mellitus.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Borges Manna L, Syngelaki A, Würtz P, et al. First-trimester nuclear magnetic resonance-based metabolomic profiling increases the prediction of gestational diabetes mellitus. Am J Obstet Gynecol. 2024. PMID: 39694165. doi:10.1016/j.ajog.2024.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。